trial

Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia

NCTId NCT06174116
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Recruiting
Enrollment 50 (estimated)
Sponsored by University of Massachusetts, Worcester
Primary completion 2026-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Recruiting
Enrollment
50 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2024-04-02
Primary completion
2026-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Lumateperone (Caplyta)

Sponsors

University of Massachusetts, WorcesterLead Sponsor
Intra-Cellular Therapies, Inc.Collaborator

Investigators

1
Xiaoduo Fan, MD, MPH, MSPrincipal Investigator

Sites

1 total
Worcester, United States

Facts & assertions

4 sourced
Enrollment
50
Phase
PHASE4
Primary Completion Date
2026-12
Status
RECRUITING
relationships
The graph out of here
drug
Lumateperone (Caplyta)
drug
lead_sponsor
University of Massachusetts, Worcester
company
collaborator
Intra-Cellular Therapies, Inc.
company
indication
Schizophrenia
indication
Schizo Affective Disorder
indication
Schizophrenia
indication
investigator
Xiaoduo Fan, MD, MPH, MS
person